Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs)
    Meeting Abstract

    O'Reilly, E. M.; Macarulla, T.; Dahan, L.; Borbath, I.; Cassier, P. A.; Guelfucci, F.; Ngami, A.; Pico de CoanĖƒa, Y.; Wainberg, Z. A.; Ambarkhane, S. V.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies
    Meeting Abstract

    Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Obesity and biliary tract cancers: Changing epidemiology
    Meeting Abstract

    Al Mahmasani, L.; Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602)
    Meeting Abstract

    Strosberg, J. R.; Zemla, T. J.; Geyer, S. M.; Knopp, M. V.; Behr, S.; Pulsipher, S.; Acoba, J. D.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis
    Meeting Abstract

    Sangro, B.; Bouattour, M.; Park, J. W.; Diaz, C.; Erinjeri, J. P.; Alves, G. V.; Gu, S. Z.; Manikhas, A.; Kuroda, H.; Suksombooncharoen, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis
    Meeting Abstract

    Heo, J.; Okusaka, T.; Yoon, J. H.; Sangro, B.; Chan, S. L.; Erinjeri, J. P.; Matos, M.; Decaens, T.; Chen, E. X.; Beg, M. S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Automated radiomics model for preoperative pancreatic neuroendocrine tumor grade prediction
    Meeting Abstract

    Chandra, P.; Nasar, N.; Ghahremannezhad, H.; Soares, K.; Balachandran, V. P.; Drebin, J. A.; D'Angelica, M. I.; Kingham, T. P.; Jarnagin, W. R.; Chakraborty, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between immune-related adverse events and prognosis after immune checkpoint inhibitor in hepatocellular carcinoma: A meta-analysis and systematic review
    Meeting Abstract

    Hwang, S. Y.; Rezaee-Zavareh, M. S.; Attia, A. M.; Kaymen, E.; Tran, N. H.; Abou-Alfa, G. K.; Singal, A.; Yang, J. D.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository
    Meeting Abstract

    Cowzer, D.; Walch, H. S.; Atri, P.; Shah, F.; Huq, R.; Khalil, D. N.; Park, W.; Yeh, R.; Do, R. K. G.; Basturk, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA)
    Meeting Abstract

    Janjigian, Y. Y.; Van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save